CorMedix Inc. (CRMD)

CorMedix Inc.'s stock price has fluctuated, decreasing by 34.25% over the last 12 months and having a year-to-date return of -31.90% as of May 8, 2026, but increasing by 9.54% in the past month. As of May 6, 2026, the share price was $8.05, a 31.08% decline from May 7, 2025. A share repurchase program of up to $75 million was approved in February 2026, and the acquisition of Melinta Therapeutics in August 2025 transformed CorMedix into a company with multiple commercial products.

Information regarding the specific demand seasonality for CorMedix, Inc.'s products and services is not explicitly detailed; however, seasonality is a recognized aspect for analysis for the company's stock performance.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases, primarily in the United States. Their lead product, DefenCath, is an FDA-approved antimicrobial catheter lock solution for reducing catheter-related bloodstream infections in adult hemodialysis patients. Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix expanded its product portfolio to include anti-infective products such as MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL, with REZZAYO approved for treating candidemia and invasive candidiasis in adults.

CorMedix Inc. primarily operates in the United States. The company is based in Parsippany, New Jersey, with a corporate office in Berkeley Heights, New Jersey.

CorMedix Inc. has generally maintained a positive brand reputation among analysts, receiving an average rating of "Moderate Buy" from eight brokerages with an average 12-month price target of $15.00. Danelfin AI gives CorMedix a "Buy" rating with an AI Score of 7/10, indicating a 59% probability of outperforming the market in the next three months. However, the stock's decline over the past year could be perceived negatively by some investors.

CorMedix Inc. has a mixed ownership structure, with individual investors holding approximately 59% of shares. Institutional investors hold a notable share, with 200 institutional owners holding 40,987,717 shares as of May 4, 2026. Major institutional shareholders include BlackRock, Inc., Deep Track Capital, LP, and Vanguard Group Inc.